Stifel cuts Celcuity stock price target on refined market model

Stifel has reduced its price target on Celcuity Inc (NASDAQ:CELC) stock to $150 from $175, while keeping a Buy rating. Celcuity's shares are currently trading at $86.60, down 57% from its 52-week high of $151.02, but have shown a strong 67% return over the past year. The firm believes the stock is overvalued at current levels. Celcuity's management reiterated confidence in shipping commercial product by late third quarter 2026.

The company started an Expanded Access Program last week to distribute gedatolisib to eligible patients before formal commercial shipments. Celcuity's wholesale acquisition cost for Revtorpyk is now $30,000 per month, up from an estimated $26,000 per month. Management provided guidance of about 20% gross-to-net at steady state and disclosed mean gedatolisib treatment cycles used in VIKTORIA-1 patients.

Celcuity is optimistic about continued gedatolisib dose-escalation in the Phase 1 metastatic castration-resistant prostate cancer trial, which is currently at 300mg. The updated estimates mainly reflect refined market model inputs and higher estimates for fiscal 2026 and beyond selling, general, and administrative expenses. An InvestingPro tip indicates that analysts do not expect the company to be profitable this year, but it maintains a strong current ratio of 12.31, indicating solid liquidity for its commercial launch plans.

Investors can access the Pro Research Report for more detailed insights into Celcuity's financial health and growth prospects.